Welcome to Rare Aware Portal!
Rare Aware is a unified online presence for Takeda’s Rare Immunology and Rare Genetic Disease portfolios aiming to educate and engage HCPs to drive awareness and elevate Standards of Care.
Use the buttons in the menu above to navigate to your relevant therapy area or product.
By registering, you can access personalised content, learning materials, events and other useful resources helping you support your patients
FOR MORE INFORMATION ON RARE AWARE, PLEASE LOGIN.
Therapy Areas
Products
1. TAKHZYRO (lanadelumab) Summary of Product Characteristics approved in UAE,13 October 2022. TAKHZYRO (lanadelumab) Summary of Product Characteristics approved in Kuwait, 13 October 2022.
2. HYQVIA UAE Summary of Product Characteristics January 2024. 3. Cuvitru UAE Summary of Product Characteristics January 2024.